|
|
NEUROENDOCRINOLOGY
LETTERS
including
Psychoneuroimmunology, Neuropsychopharmacology,
Reproductive Medicine, Chronobiology
and Human Ethology, ISSN 0172–780X
|
|
|
Published
in NEL
Vol.24 No.1/2, Feb-Apr 2003
KEY WORD INDEX
Vol. 23, 2002
|
2003;
24:111–112
pii: NEL241203X02
[View
pdf 210kb]
|
|
25-hyroxycholesterol
141;
2-Nitropropane 335;
6-hydroxymelatonin sulfate S1:88;
ACTH 85;
actinic keratoses S2:48;
action spectrum S2:17;
actomyosin 13;
adaptation S4:39; S4:98;
adenosine 273;
adrenal gland 21;
adrenal hyperplasia and idiopathic hirsutism 309
age-related macular degeneration 370;
aging 49; 55; S1:9; S1:17; S1:14; S1:20; S2:9; S3:5-144
alanine aminopeptidase 105;
alarm substances 79
allomimesis S4:15;
Alzheimer's dementia 155
Alzheimer's disease 199; S1:20;
amalgam 459;
analysis S1:30;
androgen 309; 321; S1:45;
angiogenesis 396;
animal S3:5-144
animal evidence S2:79;
animal studies S2:84;
anti-androgens 61;
antioxidant 385; 459; S1:3; S1:39;
antioxidant enzymes 345;
anxiety 199;
apoptosis 193; S1:50;
APUD cells 119; 447;
APUD-system 281
Arctic S2:84;
aspirin-sensitive asthma 281;
asthma bronchiale 243
astrocyte 325;
ATP 273;
atropine 432;
attention deficit hyperactivity
disorder 45;
attraction S4:92;
attributable fraction S2:71;
attributable risk S2:71;
autism 303;
autocrine/paracrine feedback 273
automatic movie analysis S4:15;
Barker hypothesis 219;
basal cell carcinoma S2:48;
battle (pitched) S4:55;
benzodiazepines 55; S1:9
beta-adrenoceptors 27;
bicalutamide 61;
biogenic amines 119
biological clocks S2:23;
biological plausibility S2:4;
birds 161;
blind people S2:84;
blood pressure 170
body mass index S4:81;
bone metabolism 417;
bowen's disease S2:48;
brain circuits S4:92;
brain 440;
breast cancer S2:57;
bright light therapy 109;
bursin S1:61;
C6 glioma 325;
camp S1:67;
Campbell rats 365;
cancer 61; 193; 239; S1:24; S1:39; S1:45; S1:50; S1:55;
S2:4; S2:14; S2:17; S2:28; S2:48; S2:52; S2:57; S2:71;
S2:82; S2:84;
cancer mechanisms S2:43; S2:79;
cancer patients S1:30;
cancer prevention S2:28;
carcinogens S1:39;
cardiac injury 133;
cardiovascular system S1:79;
cathepsin D and L 105;
cell plasticity 447;
cell proliferation 335; S1:73;
cellular phone S1:88;
cerebral cortex 396;
c-Fos 325; 452;
c-Fos gene expression 315;
chicken 161; S1:67; S1:61;
children 133;
choroidal neovascularization 370;
chromogranin B 209;
chronic fatigue 459;
chronic renal failure S1:97;
chronobiology S2:23;
chronomics 170
circadian S2:17;
circadian biology S2:82;
circadian cardiovascular rhythms 170
circadian disruption S2:57;
circadian rhythm 239; 243; S1:97;
circasemiannuals 170
classification 351;
clinical, experimental and epidemiological research S2:4;
clock genes S2:79;
Club of Friends 76
cognition 219; S4:105; S4:67;
cognitive domains S4:98;
cognitive impairment S1:20;
colon cancer S1:50; S1:55;
colorectal carcinoma 239
combination, clinical trial 109
conflict S4:23;
conflict management 379;
confounding S2:71;
consensus and controversy S2:71;
contemporary medicine 5;
core body temperature 213;
cortisol 79; S1:17;
CRF 85;
crosstalk S2:43;
culture of rat granulosa cells141
cutaneous tumors S2:48;
cyproterone acetate 309;
cytokines 10;
cytoprotection 391
daily rhythm 417;
D-amphetamine 45;
Darwinian algorithms S4:98;
Darwinian psychiatry S4:31;
dehumanization 5;
depression 199;
depression, social dominance S4:105;
development S2:37;
DHEAS S1:17;
diabetes 226; 437;
diabetes mellitus 432;
diagnosis S1:92;
diagnostics 351; 356;
diffuse neuroendocrine system 119;
diltiazem 432;
diseases of aging S2:9
divorce S4:47;
DNA S1:39;
DNA damage S2:9;
DNA synthesis 335;
dominance S4:47;
dopamine S4:92;
Dronabinol 387;
dynamic systems S4:15;
ecstasy 259;
EHF irradiation 315;
electric light S2:57;
emotions S4:105;
endocrine 447;
endocrine disruption S2:37; S2:43;
endocrine pathways S2:79;
endocrine systems S2:4; S2:61; S2:71; S2:82; S2:84;
endocrinology 8;
endogenous opioids 193;
end-stage renal disease S1:97;
enkelatin 85;
enterochromaffin cells 121;
entrainment S2:23; S2:82;
environment S4:39;
enzymatic processing 33;
epidemiological studies S2:61; S2:84;
epidemiology S2:48; S2:79; S2:82;
epilepsy 10; 387;
Epitalon 411; 452;
equilibrium model 219
estradiol 155; 309; 405; S1:17;
estrogen 95; 321;
estrogen receptors 95;
estrogen receptor-a and b 2:37;
estrone 155;
ethics S4:98;
evolution S4:55;
evolutionary psychology S4:39; S4:105; S4:98;
experimental tumors S1:24;
exposure surrogate S2:71;
extended family S4:47;
extrapineal synthesis S1:92;
fatty acids S2:52;
fear 79;
fecundity S4:47;
feedback S2:43;
female attractiveness S4:81;
fenoterol 141;
Feulgen reaction 391;
Fischer 344
fluorescein angiography 370;
fMRI scanning S4:92;
focal cerebral ischemia 249
free radical scavenging S2:9;
free radicals S1:3;
Freund's adjuvant arthritis 49;
functional impairment S4:31;
functional teratology 427;
gastrointestinal tract 121
gender differences 440;
gene chip S4:105;
gene switches 447;
genetics S4:39;
ghrelin 432;
global magnetic pollution 170
glucagon secretion 432;
glucocorticoids 33;
GnRH 101;
goitre 351;
gonadotrophins 101
graphical methods S2:71;
growth hormone 391;
growth processes S1:73;
guinea pig 115
healing processes 4
hearing organ 455;
heart 13;
heart rate variability 170
histopathological changes 335;
historical anthropology 77
holistic mode of thinking 5
homeostasis 105;
homosexual mate selection 299;
homosexuality 287
hormone replacement therapy 243;
hormone-dependent cancer S2:61;
hormone-dependent carcinogenesis S2:4;
hormones 379; 417;
HPA axis 45;
human 291; S3:5-144
human hypothalamus 33;
human patients 365
human pheromones 79;
human vascular endothelial cells95;
hydrocortisone 105;
hyperandrogenism 309;
hypercholesterolemia S1:79;
hypertension S1:79;
hypoglycemia 226;
hypothalamus 315;
hypoxia 231;
IFN-g 325;
IGF-I 437;
IGF-I S1:17;
IL-6 325;
imipramine 109;
immune system 161; 447;
immunity 8; S1:61; S3:5-144
immunocytochemistry 209;
immunotherapy 255;
industrialization S4:47;
inferential communication S4:15;
infidelity S4:47;
inflammation 161;
inpatients 109;
insomnia S1:118;
insulin 437;
interaction rapport S4:15;
interleukin-1 411;
interleukin-2 255; 341;
interleukin-8 133;
internal cancer S2:4;
intracellular energy luxes 13;
intracerebroventricular 27;
invertebrate neural tissues 329;
invertebrates 85;
iodine deficiency 351;
ischemia-reperfusion 115;
isoquinoline alkaloids 329;
Jansky-Bielschowsky 387;
jealousy S4:23;
jet-lag S1:118; S1:9;
kin selection S4:55;
|
late
sleeper 385;
latitude S2:71; S2:84;
L-dopa 61;
leech 209;
leptin 149;
lesion
S4:31;
lethal male raiding S4:55;
leucine aminopeptidase 105;
LIF 325
light S2:4; S2:14; S2:17; S2:61; S2:71; S2:82;
light at night S2:23; S2:28; S2:82; S2:84;
light deprivation S2:28;
light during darkness S2:52;
light exposure S2:9;
light-dark cycle S2:79;
Linda Mealey S4:12;
lipid peroxidation 345;
luzindole S1:67;
lysosomal lipases 105;
lysosomes 105;
magnetic field S1:88; S1:84;
major depressive disorder 109;
mammals S1:61;
Marinol 387;
marriage S4:47;
mate choice S4:47; S4:92;
mate guarding S4:23;
mate preferences 291;
mate selection S4:81;
mate value S4:81;
mathematical model S2:43;
mathematical modeling 13;
mating S4:23;
mating types 287;
MDMA 259;
melanoma S2:48;
melatonin 49; 55; 115; 121; 213; 239; 243; 281; 309; 335;
341; 345; 385; 391; S1:3; S1:9; S1:14; S1:17; S1:20; S1:24;
S1:30; S1:39; S1:45; S1:50; S1:61; S1:67; S1:73; S1:79;
S1:84; S1:88; S1:92; S1:97; S1:118; S2:4; S2:14; S2:17;
S2:23; S2:28; S2:61; S2:82; S2:84;
melatonin circadian rhythm S1:14
melatonin receptors S1:50; S1:55;
melatonin shower 385
melatonin suppression S2:9; S2:52
membranes cancer initiation S1:39;
menopause S2:37;
menstrual cycle 291;
mental capacities 427;
mental disorder S4:31;
mercury 459;
metal exposure 459;
microarrays S4:105;
mind S4:105;
minor illness 219;
mirror neurons S4:15;
mitochondria 231
molecular clocks S2:79;
Monoamines 259;
morphine 21; 85; 95; 161; 193; 329;
motion energy detection S4:15;
motor S4:67;
MT1 receptor S1:55;
MT2 receptor S1:55;
multiple sclerosis 199;
myocardial infarction 391;
myoclonus 387;
mysticism S4:98;
myths S4:98;
N-acetyl-7-glucosaminidase105;
naltrexone 255; 341;
NCL 387;
necrosis and degeneration 335
neoplasia 193;
nerve terminals 273;
nervous system 226
neurobiological traits 379;
neurodegeneration S2:9;
neuroendocrine prophylaxis 427;
neuroevolutionary psychobiology S4:105;
neurohormonal theory 299
neurohypophysial astrocytes273;
neurohypophysis 273; 396;
neuroimmunity 8;
neuroimmunoendocrinology 119;
neuroimmunomodulation 255;
neuroimmunotherapy 341
neuropeptide Y 149;
neuroprotection 249;
neuropsychiatric disorders 45;
neurotransmitters 379;
neutral sphingomyelinase 411;
NIDDM 226;
nitric oxide 21; 95; 101; 193; 281;
NMDA receptors 345;
nodular goitre 356;
nonverbal communication S4:15;
norepinephrine 49;
noxious mechanical stimulation 315;
olfactory communication 79;
oncogenes 452;
opiates 161;
opioid peptides 85;
opioid system 255
opioids S1:61;
oppositional-defiant disorder45;
optical coherence tomography 370
oral contraception 291
osmotic stress 452;
ovariectomy 405;
ovary 27;
oxidative stress S1:3; S1:39;
oxytocin 273;
ozone S2:14;
P300 226;
PACAP 141; 249;
pair bonding S4:47;
pancreas 432;
paraneuron 447;
partner preferences 299;
peptide Epitalon 365;
peptide hormones 119;
peptides S3:5-144
peritonitis 161;
perivascular cells 396
personality 379;
pharmacology S3:5-144
phenylonephrine 141;
pheromone receptors 287;
pheromones 287; 291;
photodynamic therapy 370;
photoreceptor S2:17;
physics of light S2:79;
physiology S3:5-144
phytoestrogens S2:37;
pineal S2:82;
pineal body S3:5-144
pineal gland 49; 365; 443; S1:61; S1:73; S1:84; S2:28;
S2:52;
pinealocyte 405; 443; 452;
Piracetam 387;
PISA 2000 427;
pituitary hormones 149
pituitary tumor 321;
plasma 459;
platelets 281;
play S4:105;
popular version 3
postnatal development 231;
posttranslational 33;
proceptivity S4:92;
progesterone 27; 141;
prohormone convertases (PC1; PC2) 33;
prolactin 61;
prolactinoma 321
proliferation S1:50; S1:67;
propranolol 432;
prostate S1:45;
prostate cancer 61;
protean behavior S4:15;
protection S1:39;
psychiatric disorders S4:105;
psychopathology S4:39;
psychotic episodes 259
PTSD 199;
pulmonary edema 115;
purinergic receptor 273;
pyridoxine 213
quality of life 459
questionnaire 459;
radioimmunoassay 432;
receptor S1:45;
receptor biology S2:43;
reductionistic thinking 5;
religiosity S4:98;
removal 459;
reticuline 329;
retina S3:5-144
retinal degeneration S3:5-144
Retinitis Pigmentosa 365;
retinopathy 226;
rituals S4:98;
RZR/ROR& receptor S1:55;
salivary cortisol 45;
schizophrenia 199;
scientists in exile 379;
scorpion 133;
secretion S1:73;
secretolytin 209
self-deception S4:15;
serotonin 49;
serum folate 155;
sex hormones S4:67;
sexual attraction 291;
sexual maturation 101;
sexual orientation 299;
sexual selection S4:55;
SHBG 155;
shift work S2:82; S2:84;
signal transduction 411; S1:67;
single thyroid nodules 356;
skin cancer S2:4; S2:48;
sleep 213;
sleep deprivation 385;
sleep disorders S1:9; S1:20;
Society of Integrated Sciences 272
somatostatin-receptor 440;
spastic 387;
spatial S4:67;
splenocytes S1:67;
squamous cell carcinoma S2:48;
STAT 325;
statistical deviance S4:31;
Stefan Zweig 4
stress 85; 199; 259; 411; 452; S1:3; S1:39;
stroke prevention 170
suffering S4:31;
sulfur metabolism 303
sulphonylurea 437
sunlight S2:14;
superior cervical ganglia 443;
superior ovarian nerve 27
suppression 33
surgical castration 455;
sympathectomy 443;
sympathetic hyperactivity 259;
synchronization S4:15;
syn-disciplinary S2:4;
temperament 379;
testis 231;
testosterone 155; 231;
tetrahydroisoquinoline alkaloids 329
tetrahydropapaveroline329;
THC 387;
The Bird of Happiness286
the built-in biological week 170
therapeutic application S1:118;
therapeutic use S3:5-144
thiamine tetrahydrofurfuryl “ disulfide 303;
thioglycollate 161
thymic hormones S1:61;
thymocytes 411;
thyroid gland S1:73;
thyroid hormones S1:73;
tissue specificity S2:37;
total DDT-levels in human milk 427;
troponin I 133;
tumor burden S2:79;
tumor growth S1:92;
ubiquitous exposure S2:61;
ultrastructure 405; 443;
ultraviolet S2:14;
urinary arsenic 303;
UV S2:14;
waist-to-hip ratio S4:81;
war causation S4:55;
warfare 'primitive' S4:55;
vascular endothelial cells 21;
vasopressin 33; 273;
wealth S4:47;
verbal S4:67;
verteporfin 370;
VIP 141; 249;
vomeronasal organ 287;
xenobiotic ligand S2:43;
yohimbine 432;
Zdenek Klein Award for Human Ethology75; S4:8;
Zonisamide 387
|
|
|
__________________________________________________________
Copyright © Neuroendocrinology Letters 2003
Society of Integrated Sciences
All rights reserved. No part may be reproduced, stored in a
retrieval system, or transmitted in any form or by any means,
electronic, mechanical, photocopying, recording, or ortherwise,
without prior written permission from the Editor-in-Chief.
The
latest statistics from the www.nel.edu
|
|
|
